IHS Hogs More Data

Recs

1

Panic 2008... Profit 2009!

Fool -- Now's the time to invest! David and Tom Gardner's new book reveals their strategy for million dollar wealth.

Wall Street has smiled on the four deals IHS (NYSE: IHS) has completed thus far this year. In exchange for the $200 million it's shelled out in acquisitions, IHS has seen its shares increase 18% since the beginning of 2007. But to keep that growth moving, management will have to keep hunting for new targets to acquire.

IHS develops sophisticated databases and decision tools for industries such as energy, aerospace, and engineering. Its marquee customers include Intel (Nasdaq: INTC), General Motors (NYSE: GM), and ExxonMobil (NYSE: XOM).

Boosted by acquisitions, second-quarter revenues increased 16.5% to $154.9 million. Net income surged 44% to $18.6 million, or $0.32 per share, in the same period. For the first half of 2007, cash flow from operations totaled about $65.8 million, and the company's got $212.3 million in the bank.

Besides its cash hoard, IHS's $2.6 billion market cap is also helpful in pulling off deals. Look at last week's acquisition of Jane's Information Group, which was funded by the $183.5 million in shares IHS issued to do the deal.

Founded more than 100 years ago, Jane's maintains databases and specialized publications for the defense, aerospace, and security sectors. Over the past couple of years, the company has shifted its print business to digital forms. That's resulted in low-single-digit revenue growth, but IHS believes it can bump up the growth rate to the low double digits. In addition, IHS's proven cost-cutting prowess should help the combined companies reap considerable savings.

There should also be considerable cost savings. IHS has demonstrated that it knows how to find efficiencies in its platform.

As I've mentioned in prior articles, IHS has a solid business with strong barriers to entry, a compelling value proposition, and a predictable recurring revenue stream. The Jane's deal should also be a nice boost to its platform. All in all, Foolish investors might want to consider carving off a slice of IHS for themselves.

Further Foolishness:

Intel is a Motley Fool Inside Value pick. Discover more of the best Wall Street values with a free 30-day trial subscription

Fool contributor Tom Taulli, author of The Complete M&A Handbook, does not own shares mentioned in this article. He is currently ranked 1,831 out of 30,414 in Motley Fool CAPS.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 529996, ~/articles/articlehandler.aspx, 1/9/2009 12:48:14 AM

Sign up for FREE Motley Fool site access to keep reading:

“IHS Hogs More Data”

Signing up allows you to comment on articles and on the discussion boards.

It's completely FREE and will take only 10 seconds.

Privacy / Legal Information

We will use your email address only to keep you informed about updates to our web site and about other products and services that we think might interest you. The Motley Fool respects your privacy. Please read our Privacy Statement

.

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

What Fools Are Saying

Most Recommended

Jan 8 at 4:06 PM

Market Summary

DJIA 8,742.46 -27.24 -0.31%
S&P 500 909.73 +3.08 +0.34%
NASD 1,617.01 +17.95 +1.12%
Sponsored by:

Related Tickers

IHS, Inc.

CAPS Rating 2/5 Stars

$40.05

-0.92 (-2.25%)

Outperform76

Underperform8

Rate This Stock